Genentech Inc., or Genetic Engineering Technology, Inc., is a biotechnology corporation, founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert Boyer. It is considered to have founded the biotechnology industry. One of its founders, Boyer, is considered to be a pioneer in the field of recombinant DNA technology. In 1973, Boyer and his colleague Stanley Norman Cohen demonstrated that restriction enzymes could be used as "scissors" to cut DNA fragments of interest from one source, to be ligated into a similarly cut plasmid vector. While Cohen returned to the laboratory in academia, Swanson contacted Boyer to found the company. Boyer worked with Arthur Riggs and Keiichi Itakura from the Beckman Research Institute, and the group became the first to successfully express a human gene in bacteria when they produced the hormone somatostatin in 1977. David Goeddel and Dennis Kleid were then added to the group, and contributed to its success with synthetic human insulin in 1978.
Campaign Finance$489,868 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Genentech Inc
Names of Lobbyists
Firm Hired Amount Genentech Inc $7,632,368
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Food Industry,
- Homeland Security,
Most Frequently Disclosed Bills
Bill No. Title H.R.1548 Pathway for Biosimilars Act H.R.1 American Recovery and Reinvestment Act of 2009 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.1427 Promoting Innovation and Access to Life-Saving Medicine Act H.R.1260 Patent Reform Act of 2009 S.515 Patent Reform Act of 2009 H.R.3962 Affordable Health Care for America Act S.726 Promoting Innovation and Access to Life-Saving Medicine Act S.301 Physician Payments Sunshine Act of 2009
RegulationsMentioned in 41 dockets; Submitted to 7 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Genentech Inc" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Genentech Inc
- Toggle 26 FDA Proposal to Withdraw Approval; Notice of Opportunity for a Hearing for the Breast Cancer Indication for Bevacizumab (Avastin) 2010
- Toggle 1 FDA Draft Guidance for Industry on Adaptive Design Clinical Trials for Drugs and Biologics 2010
- Toggle 1 FDA Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments 2010
- Toggle 1 FDA Draft Guidance for Industry on Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products; Availability 2009
- Toggle 1 FDA Draft Guidance for Industry on Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment 2010
- Toggle 1 FDA Guidance for Industry: Technical Considerations for PEN, JET, and Related Injectors Intended for use With Drugs and Biological Products; Availability 2009
- Toggle 1 FDA Draft Guidance for Industry on Assay Development for Immunogenicity Testing of Therapeutic Proteins; Availability 2009
Mentions in Document Text
View all mentions data for Genentech Inc
- Toggle 378 FDA Proposal to Withdraw Approval; Notice of Opportunity for a Hearing for the Breast Cancer Indication for Bevacizumab (Avastin) 2010
- Toggle 3 FDA Investigational New Drug Applications; Co-Development of Investigational Drugs 2010
- Toggle 2 FDA Draft Guidance for Industry on Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Agents for Treatment 2010
- Toggle 2 FDA Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments 2010
- Toggle 2 FDA Current Good Manufacturing Practice Requirements for Combination Products 2009
- Toggle 2 FDA Petition Requesting that the Agency not Approve ANADA 011-557 Before Expiration of the 30-month Stay on March 29, 2011 2009
- Toggle 2 CMS Medicare Advantage Program (Title II) 2010
- Toggle 2 FDA Guidance for Industry: Technical Considerations for PEN, JET, and Related Injectors Intended for use With Drugs and Biological Products; Availability 2009
- Toggle 1 FDA Draft Guidance for Industry on Non-Inferiority Clinical Trials; Availability 2010
- Toggle 1 EPA Supplemental Guidance for SIP Submissions to Meet the Requirements for Section 110(a)(1) of the CAA for the SO2 NAAQS 2010
Advisory Committees1 person on 1 committee
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Genentech Inc" that sat on federal advisory committees.
- Toggle National Science Foundation 1 person on 1 committee